Fig. 1
From: Non-neuronal cholinergic activity is potentiated in myasthenia gravis
PBMC-derived ACh and cholinergic content differs in patients with MG from that in healthy controls. a PBMC-derived ACh per million cells was obviously increased in MG patients (n = 125) compared with controls (n = 50) (p = 0.0003). b High-affinity choline transporter (ChT1) mRNA expression was higher in MG patients (n = 15) than that in control (n = 6) (p = 0.0449). c Choline acetyltransferase (ChAT) mRNA relative expression showed no obvious change (p = 0.9061). d A sharp decrease in acetylcholinesterase (AChE) mRNA expression was observed between MG patients and controls (p = 0.0011). (c-d; n = 10 for control, n = 36 for MG)